FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	S IN BENEFICIAL	OWNERSHIP

l	UMB APPRO	VAL					
	OMB Number:	3235-0287					
l	Estimated average burden						
l	hours per response:	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

Name and Address of Reporting Person* Shi Mingshong				2. Issuer Name and Ticker or Trading Symbol NeoStem, Inc. [NBS]							Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Shi Mingsheng											X X	Officer (g	give title		10% Owi		
(Last) (First) (Middle) 859 PANXU ROAD CANGLANG DISTRICT					3. Date of Earliest Transaction (Month/Day/Year) 06/17/2010							See Remark No 1. below					
(Street) SUZHOU JIANGSI PROVIN	U F		215002	4	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line)	ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3) 2. Trans Date				2. Transact	2A. Deemed Execution Date,		3. 4. Securities Acquii Transaction Disposed Of (D) (In		es Acquirec	l (A) or	5. Amount Securities Beneficial Owned Fo	5. Amount of Securities Beneficially Owned Following Reported		Direct II Indirect E tr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code V	Amo	unt	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)					
			Table II - D					uired, Dis , options					wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	Code		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date of S (Month/Day/Year) Unit		7. Title and of Securiti Underlying Derivative (Instr. 3 an	es J Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v			Date Exercisable	Expira Date	tion	ion Title Am		(Instr. 4					
Warrants (right to buy)	\$2.36	06/17/2010		A		600,000 ⁽¹⁾		(2)	06/17/2	2020	Common Stock	600,000	\$0	600,0	00	D	

Explanation of Responses:

- 1. The warrants were granted to the reporting person under the Non-U.S. Based Equity Compensation Plan of NeoStem, Inc. (the "Company").
- 2. The warrants are subject to vesting on the last day of the month in which certain performance conditions or business milestones for Suzhou Erye Pharmaceuticals Company Ltd., a 51% owned subsidiary of the Company, are achieved.

Remarks:

(1) Chairman of the Board of Directors of Suzhou Erye Pharmaceuticals Company Ltd. (2) Exhibit 24 - Power of Attorney

/s/ Catherine M. Vaczy, Esq.,

Attorney-in-fact for Mingsheng 06/18/2010

<u>Shi</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these presents, that Mingsheng Shi hereby constitutes and appoints each of Robin L. Smith, Catherine Vaczy, Esq. and Alan Wovsaniker, Esq., his true and lawful attorney-in-fact with respect to NeoStem, Inc to:

- execute for and on behalf of the undersigned Schedules 13D and 13G, Form ID, and Forms 3, 4, and 5 in accordance with Sections 13 and 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete the execution of any such Schedules 13D or 13G, Form ID, and Forms 3, 4, or 5, and the timely filing of such forms with the United States Securities and Exchange Commission and any other authority; and
- 3. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, including without limitation the execution and filing of a Form 4 with respect to a transaction which may be reported on a Form 5, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary and proper to be done in the exercise of any of the rights and powers herein granted, as fully and to all intents and purposes as he might or could do in person, with full power of substitution and resubstitution, hereby ratifying and confirming all that such attorney-in-fact, or his substitute or substitutes, shall lawfully do or cause to be done in virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming any of the undersigned's responsibilities to comply with Sections 13 and 16 of the Securities Exchange Act of 1934.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this ___ day of November, 2009.

Mingsheng Shi